Targeted metabolomics panels provide absolute quantitation to further scientific discovery and inflammation research
MORRISVILLE, N.C., Jan. 17, 2023 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant expansion of its Inflammation Portfolio with the launch of new Targeted Panels studying Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation. The Portfolio also includes the recently launched Oxysterols Targeted Panel. Metabolon’s Inflammation Portfolio detects and provides deeper insights into a wide range of known bioactive mediators of inflammation for the prediction, early detection, and monitoring of disease states, including chronic pain, neuro-inflammatory disease, neurodegeneration, and cardiovascular diseases.
“Metabolomics is key to understanding the complex interplay between inflammation and disease, offering a holistic view of the metabolic changes that occur within an organism,” said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon. “Our newly developed Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation Targeted Panels utilize the power of metabolomics to unlock new insights and treatments for inflammatory conditions to get closer to understanding and combating many major diseases.”
Endocannabinoids are endogenous lipid-based neurotransmitters that bind to cannabinoid receptors (CBRs). They are produced naturally by the human body and regulate a wide range of physiological and cognitive processes, including fertility, pregnancy, pre-and postnatal development, motor control, appetite, food intake, pain sensation, mood, memory acquisition, and learning. Disorders of the endocannabinoid system are related to several neuro-inflammatory diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis. The Metabolon Cannabinoid Targeted Panel measures 31 cannabinoids and provides insight into the therapeutic potential of cannabinoids in key disease states such as chronic pain and neuro-inflammatory disease.
Sphingolipids are a class of lipids linked to inflammatory disease states, including neurodegeneration and cardiovascular diseases. The Metabolon Sphingolipid Targeted Panel measures changes in 61 lipid species across five lipid classes with strong links to inflammation. It detects known bioactive mediators of inflammation enabling insights into key disease areas such as cardiovascular, neurodegenerative, dermatitis, and more.
Lipid mediators of inflammation are a group of molecules involved in immune response and inflammation. They are derived from the breakdown of fatty acids and play a role in a variety of functions, including the regulation of blood flow and the modulation of pain and swelling. The balanced production and regulation of lipid mediators of inflammation are important for maintaining normal immune function and preventing chronic inflammation. The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 analytes associated with metabolic consequences of widespread inflammatory disease to identify biomarkers and their quantitative changes.
To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/.
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research. Over 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon’s Global Discovery Panel is enabled by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable metabolomics and lipidomics solutions supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
Metabolomics, the large-scale study of all small molecules in a biological system, is the only ‘omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic as well as external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
SOURCE Metabolon, Inc.